Adicet bio to host investor webcast to discuss updated clinical data from ongoing adi-001 phase 1 trial in patients with relapsed or refractory aggressive b-cell non-hodgkin's lymphoma (nhl)

Redwood city, calif. & boston--( business wire )--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for cancer, today announced that the company will host a webcast presentation on sunday, december 11, 2022 at 9:00 a.m. est to discuss the most recent data-cut from its ongoing phase 1 study evaluating the safety and tolerability of adi-001 for the potential treatment of relapsed or refractory b-cell nhl.
ACET Ratings Summary
ACET Quant Ranking